ADAR1 Capital Management, LLC

October 15, 2026

INM: No recent news reported. There were no new announcements or events involving InMed Pharmaceuticals in the past week. The only article listed concerns Liquidia, which does not affect INM directly. Therefore, no new information is available to influence the company's outlook at this time.

October 9, 2026

Tenax Pauses TNX-103 Trial Enrollment, Seeks FDA Meeting. Tenax Therapeutics has temporarily paused enrollment in its LEVEL-2 trial for TNX-103 to amend study criteria. The company has also requested a meeting with the FDA to discuss these changes. This development is significant as it involves a key clinical trial, and the stock is currently trading near its 52-week low.

October 2, 2026

NXTC noted in after‑hours market coverage. NextCure Inc. appeared in after‑hours market reports today. The stock was highlighted in a ChartMill after‑hours session overview and listed among twelve health‑care stocks that moved in Thursday’s after‑market trading. The coverage suggests recent investor attention, while the stock remains near its recent support level.

September 28, 2026

Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial. Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.

October 13, 2026

Palvella Therapeutics Shares New Data at Dermatology Conference. Palvella Therapeutics presented three posters at the Fall Clinical Dermatology 2026 conference, sharing new data on microcystic lymphatic malformations and DSAP. This update highlights ongoing research in the company's key therapeutic areas. Meanwhile, HC Wainwright lowered its price target to $246 while maintaining its stance on the stock.